Autoimmune diseases are on the rise in the U.S., with as many as 50 million Americans affected. Learn what causes them—and which symptoms could help pinpoint your problem.

Rosnilimab acts as an agonist to stimulate PD-1, killing those cells with high PD-1 expression and pushing others into an ...

The new biotech Elevara plans to initiate Phase II testing of its lead candidate ELV001 as an add-on treatment for rheumatoid ...

First-in-human data validating direct targeting of NETs as a novel therapeutic approach in autoimmunity and inflammatory diseases- DNASE1L3 ...

The presentation is available for download on the Anaptys website here.

Treatment with TNF-α inhibitors may be safer than IL-6 inhibitors in terms of cardiovascular outcomes when managing patients with RA and T2D.

New data reinforce rosnilimab’s efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, from Week 12 to Week 28 regardless of prior advanced ...

A study presented at ACR Convergence 2025 suggests that GLP 1 receptor agonists reduce flares and systemic inflammation in Rheumatoid Arthritis (RA) patients.

Several factors — but not older age — increased infection risk with the use of non-TNF biologics following first-line ...

An observational cohort study uses multi-omics profiling to identify distinct biomarkers that could aid in the earlier ...

New research presented at ACR 2025 shows GLP-1 receptor agonists, used for diabetes and obesity, may reduce rheumatoid ...

Inflammatory arthritis resulting from immune checkpoint inhibitor use is immunologically unique and likely driven by T cells ...